We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Pharmacyclics Initiates Phase 1 Clinical Trial of Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

News   Apr 15, 2009

 
Pharmacyclics Initiates Phase 1 Clinical Trial of Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
 
 
Advertisement
 

RELATED ARTICLES

FDA Approves Remdesivir for COVID-19

News

The US Food and Drug Administration has approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients (≥ 12 years of age and weighing at least 40 kg) for the treatment of COVID-19 requiring hospitalization.

READ MORE

UK Researchers Set To Explore Human Challenge Studies for COVID-19 Vaccine Development

News

Researchers are set to explore a human challenge study with the virus that causes COVID-19, the first such study anywhere in the world.

READ MORE

Gut Bacteria May Be Responsible for Adverse Effect of Parkinson's Drug

News

Bacteria in the small intestine can deaminate levodopa, the main drug that is used to treat Parkinson's disease.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE